It's heady times for the drug industry—or at least the US-based large-cap companies. Selling for often record multiples, their stocks seem to be soaring on some kind of super-fuel, providing $30-50 of share price lift for every dollar of earnings in the gas tank.
Can the boom continue? Hardly, believes Paul Brooke who has been watching the industry for almost 15 years as both...